Oryon Cell Therapies Appoints Burkhard Blank, M.D., as Chief Medical Officer
Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced the appointment of Burkhard Blank, M.D., as Chief Medical Officer (CMO).
